We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+13.24%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.47B
AUM Growth
+$545M
Cap. Flow
+$427M
Cap. Flow %
17.31%
Top 10 Hldgs %
69.01%
Holding
41
New
6
Increased
5
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$54.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$41.8M
3
GILD icon
Gilead Sciences
GILD
+$28.1M
4
PBYI icon
Puma Biotechnology
PBYI
+$23.7M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.8M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$49.6M
2
UAM
Universal American Corp
UAM
+$48.5M
3
CNMD icon
CONMED
CNMD
+$33.1M
4
ATHN
Athenahealth, Inc.
ATHN
+$31.6M
5
PRGO icon
Perrigo
PRGO
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 59.5%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$707M 28.68%
+3,000,000
New +$697M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$40.4B
$167M 6.79%
5,216,450
+492,000
+10% +$16.8M
VTRS icon
3
Viatris
VTRS
$20.8B
$162M 6.56%
4,145,889
– –
GILD icon
4
Gilead Sciences
GILD
$165B
$129M 5.23%
1,900,000
+400,000
+27% +$28.1M
NKTR icon
5
Nektar Therapeutics
NKTR
$2.39B
$127M 5.14%
360,000
-40,000
-10% -$8.99M
AGN
6
DELISTED
Allergan plc
AGN
$104M 4.22%
435,750
-107,250
-20% -$25M
MYGN icon
7
Myriad Genetics
MYGN
$476M
$83M 3.37%
4,325,000
+265,000
+7% +$4.7M
GHDX
8
DELISTED
Genomic Health, Inc.
GHDX
$77.4M 3.14%
2,458,100
– –
BKD icon
9
Brookdale Senior Living
BKD
$3.55B
$73.9M 3%
5,500,000
– –
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$123B
$71.1M 2.88%
650,000
-100,000
-13% -$8.8M
GILD icon
11
CALL
Gilead Sciences
GILD
$165B
$67.9M 2.75%
1,000,000
– –
SEM
12
DELISTED
Select Medical
SEM
$66.8M 2.71%
9,280,000
-1,902,400
-17% -$13.8M
BIVV
13
DELISTED
Bioverativ Inc. Common Stock
BIVV
$59.9M 2.43%
+1,100,000
New +$54.2M
LIVN icon
14
LivaNova
LIVN
$4.47B
$58.8M 2.39%
1,200,000
– –
OFIX icon
15
Orthofix Medical
OFIX
$492M
$57.2M 2.32%
1,500,000
– –
ENDP
16
DELISTED
Endo International plc
ENDP
$56.4M 2.29%
5,052,000
+1,150,000
+29% +$14.3M
PRGO icon
17
Perrigo
PRGO
$1.44B
$53.7M 2.18%
808,200
-400,000
-33% -$30.4M
CSII
18
DELISTED
Cardiovascular Systems, Inc.
CSII
$49.5M 2.01%
1,750,000
-750,000
-30% -$19.9M
ABT icon
19
Abbott
ABT
$187B
$44.4M 1.8%
1,000,000
– –
ELGX
20
DELISTED
Endologix Inc
ELGX
$43.4M 1.76%
600,000
+236,500
+65% +$15.6M
ALKS icon
21
Alkermes
ALKS
$8.11B
$42.4M 1.72%
725,000
-275,000
-28% -$15.6M
SRPT icon
22
Sarepta Therapeutics
SRPT
$1.64B
$40M 1.62%
+1,350,000
New +$41.8M
NVTA
23
DELISTED
Invitae Corporation
NVTA
$26.5M 1.08%
2,398,123
– –
ELOS
24
DELISTED
Syneron Medical Ltd
ELOS
$24.8M 1%
2,347,593
– –
PBYI icon
25
Puma Biotechnology
PBYI
$398M
$24.2M 0.98%
+650,000
New +$23.7M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Camber Capital Management held 41 positions worth $2.47B, up 28% from $1.92B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Camber Capital Management deployed $427M of net new capital in Q1 2017, opening 6 new positions and adding to 5 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 1,100,000 shares worth $59.9M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 75% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Perrigo, an estimated $30.4M trimmed.

  • Camber Capital Management's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 1,100,000 shares worth $59.9M.
  • Camber Capital Management added most to Gilead Sciences in Q1 2017, an estimated $28.1M increase.
  • Camber Capital Management's biggest Q1 2017 reduction was Perrigo, cutting an estimated $30.4M.
  • Camber Capital Management fully exited Biogen in Q1 2017, selling an estimated $49.6M.
  • Camber Capital Management's ten largest holdings make up 69% of its $2.47B portfolio in Q1 2017.
  • Camber Capital Management opened 6 new positions and closed 9 in Q1 2017.
  • Camber Capital Management's portfolio value rose 28% quarter-over-quarter to $2.47B.

Based on Camber Capital Management's 13F filing for Q1 2017, filed 15 May 2017.